XML 122 R104.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity - Summary of Restricted Stock Units (Details) - $ / shares
shares in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2019
Service Based Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding, beginning balance (in shares) 0.2  
Exercised (in shares) (0.1)  
Outstanding, ending balance (in shares) 0.1  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, beginning balance (in USD per share) $ 39.90  
Weighted average grant date fair value, granted (in USD per share)   $ 40.70
Weighted average grant date fair value, exercised (in USD per share) 36.61  
Weighted average grant date fair value, ending balance (in USD per share) $ 45.97  
Service Based Restricted Stock Units    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding, beginning balance (in shares) 0.1  
Granted (in shares) 0.1  
Outstanding, ending balance (in shares) 0.2  
Expected to vest (in shares) 0.2  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, beginning balance (in USD per share) $ 46.00  
Weighted average grant date fair value, granted (in USD per share) 48.61  
Weighted average grant date fair value, ending balance (in USD per share) 47.10  
Weighted average grant date fair value, expected to vest (in USD per share) $ 47.10  
Performance Based Restricted Stock    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding, beginning balance (in shares) 0.5  
Exercised (in shares) (0.1)  
Canceled (in shares) (0.1)  
Outstanding, ending balance (in shares) 0.3  
Expected to vest (in shares) 0.3  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, beginning balance (in USD per share) $ 36.59  
Weighted average grant date fair value, granted (in USD per share)   $ 37.27
Weighted average grant date fair value, exercised (in USD per share) 27.76  
Weighted average grant date fair value, canceled (in USD per share) 41.60  
Weighted average grant date fair value, ending balance (in USD per share) 40.31  
Weighted average grant date fair value, expected to vest (in USD per share) $ 38.71  
Restricted stock and restricted stock units, performance based    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]    
Outstanding, beginning balance (in shares) 0.4  
Granted (in shares) 0.7  
Canceled (in shares) (0.1)  
Outstanding, ending balance (in shares) 1.0  
Expected to vest (in shares) 0.6  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]    
Weighted average grant date fair value, beginning balance (in USD per share) $ 50.00  
Weighted average grant date fair value, granted (in USD per share) 48.64  
Weighted average grant date fair value, canceled (in USD per share) 51.10  
Weighted average grant date fair value, ending balance (in USD per share) 49.12  
Weighted average grant date fair value, expected to vest (in USD per share) $ 49.15